Showing 3771-3780 of 5956 results for "".
- Kowa Initiates Phase 3 Safety Trial for Glaucoma Drug Candidate NCX 470 in Japanhttps://modernod.com/news/kowa-initiates-phase-3-safety-trial-for-glaucoma-drug-candidate-ncx-470-in-japan/2482918/Nicox announced that its exclusive Japanese partner, Kowa, has officially initiated a phase 3 safety clinical trial for NCX 470 (also referred to as K-911) in Japan. NCX 470 is Nicox’s lead clinical candidate, currently undergoing phase 3 clinical evaluations
- Genentech Unveils 5-Year Data for Susvimo: Long-Term Efficacy and Durability in Wet AMD Treatmenthttps://modernod.com/news/genentech-unveils-five-year-data-for-susvimo-long-term-efficacy-and-durability-in-wet-amd-treatment/2482915/Genentech announced new 5-year data from the phase 3 Portal study, which the company says reaffirms the long-term efficacy, safety, and durability of Susvimo (ranibizumab injection) in treating wet age-related macular degeneration (AMD). The fin
- Topcon Healthcare Acquires Intelligent Retinal Imaging Systemshttps://modernod.com/news/topcon-healthcare-acquires-intelligent-retinal-imaging-systems-to-enhance-connected-care-across-primary-and-eye-care/2482909/Topcon Healthcare announced the acquisition of Intelligent Retinal Imaging Systems (IRIS), a US-based provider of cloud-based retinal screening technology. FInancial terms of the deal were not disclosed. IRIS bri
- Alcon Announces US Launch of Tryptyr for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-us-launch-of-tryptyr-for-dry-eye-disease/2482908/Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eye care professionals (ECPs) across the US can officially begin p
- EyePoint Completes Enrollment of Phase 3 Trials for Duravyu in Wet AMDhttps://modernod.com/news/eyepoint-completes-enrollment-of-phase-3-trials-for-duravyu-in-wet-amd/2482907/EyePoint Pharmaceuticals has completed enrollment of its phase 3 pivotal program with the full enrollment of the LUCIA trial, the second of two identical ongoing pivotal noninferiority trials evaluating Duravyu for the treatment of wet age-related macular degeneration (AMD). The first p
- Alcon Showcases Surgical Efficiency of Unity VCS Innovations at ASRS 2025https://modernod.com/news/alcon-showcases-surgical-efficiency-of-unity-vcs-innovations-at-asrs-2025/2482903/Alcon will showcase its latest clinical data and innovations at the 2025 American Society of Retina Specialists (ASRS) annual meeting, July 31 to August 2, in Long Beach, California. Attendees can explore Alcon’s latest surgical advancements through scientific presentations and hands-on dem
- Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindnesshttps://modernod.com/news/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapy-for-inherited-childhood-blindness/2482902/Opus Genetics announced a partnership with the Global RDH12 Alliance to advance Opus’ gene therapy program for patients with vision loss due to retinol dehydrogenase 12 (RDH12) gene mutations. The Alliance serves as a collaborative platform uniting advocacy groups dedicated to RDH
- Annexon Completes Enrollment in Phase 3 ARCHER II Trial of Vonaprument for GAhttps://modernod.com/news/annexon-completes-enrollment-in-phase-3-archer-ii-trial-of-vonaprument-for-ga/2482901/Annexon announced enrollment has been completed in the phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company remains on track to report topline data in the second half of 2026. Accordin
- Julia Haller, MD, Named CEO of Wills Eye Hospitalhttps://modernod.com/news/julia-haller-md-named-ceo-of-wills-eye-hospital/2482897/Julia A. Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital, will also become the hospital's next Chief Executive Officer. Dr. Haller assumed the expanded leadership post on July 18, succeeding longtime CEO Joseph P. Bilson, who reti
- Viatris Fails Phase 3 Study of MR-139 for Blepharitishttps://modernod.com/news/viatris-fails-phase-3-study-of-mr-139-for-blepharitis/2482893/Viatris announced that its phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. The MR-139 3001 phase 3 trial cons